NCT02502812View on ClinicalTrials.gov

Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 4, 2015

Primary Completion Date

September 24, 2015

Study Completion Date

September 24, 2015

Conditions
Cardiovascular Disease
Interventions
DRUG

Clop F1

A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

DRUG

Clop F2

A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

DRUG

Innovator

A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Trial Locations (1)

500 013

GSK Investigational Site, Telangana

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects | Biotech Hunter | Biotech Hunter